CURE
CURE

Biocure Technology Inc.

Status
Halted Pending Fundamental Change
Issued & Outstanding94,000,537
Reserved for Issuance14,510,547
Currency
CSE Index

About

Biocure Technology Inc.

Listing date
May 10, 2010
Social

Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.